Driehaus Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Driehaus Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-59,527	Closed	-$2.49M	–	529
2015 Q2	$2.49M	Buy	59,527 +9,566	+19%	+$370K	0.09%	299
2015 Q1	$1.63M	Buy	49,961 +34,761	+229%	+$1.19M	0.06%	359
2014 Q4	$483K	Buy	+15,200	New	+$431K	0.02%	439
2014 Q3	–	Sell	-159,211	Closed	-$3.6M	–	523
2014 Q2	$3.6M	Sell	159,211 -144,853	-48%	-$3.02M	0.12%	238
2014 Q1	$7.4M	Buy	304,064 +32,285	+12%	+$817K	0.23%	122
2013 Q4	$6.79M	Sell	271,779 -50,827	-16%	-$1.2M	0.25%	127
2013 Q3	$8.86M	Sell	322,606 -24,279	-7%	-$508K	0.34%	94
2013 Q2	$6.3M	Buy	+346,885	New	+$4.78M	0.28%	121

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Driehaus Capital Management's ACAD Position: Q3 2015 in Review

Driehaus Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2015, closing a stake of 59,527 shares — an estimated $2.49M sold.

Driehaus Capital Management first reported a position in ACAD in Q2 2013 and held it in 8 quarters. The position peaked at $8.86M in Q3 2013. 188 funds tracked by Wall St. Rank hold ACAD as of Q3 2015.

Driehaus Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Driehaus Capital Management sold 59,527 Acadia Pharmaceuticals shares in Q3 2015, an estimated $2.49M.
Driehaus Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Driehaus Capital Management's Acadia Pharmaceuticals position peaked at $8.86M in Q3 2013.
188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2015.

Based on Driehaus Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.